Executive summary “Depression is a disorder of mood, so mysteriously painful and elusive
in the way it becomes known to the self—to the mediating intellect—as to verge close to …

Background Depression is the single largest contributor to non-fatal health loss worldwide.
Second-generation antidepressants are the first-line option for pharmacological …

Objectives: To provide advice and guidance regarding the management of mood disorders,
derived from scientific evidence and supplemented by expert clinical consensus to formulate …

Studies on psychotropic medications decrease, discontinuation, or switch have uncovered
withdrawal syndromes. The present overview aimed at analyzing the literature to illustrate …

The process of stopping antipsychotics may be causally related to relapse, potentially linked
to neuroadaptations that persist after cessation, including dopaminergic hypersensitivity …

Introduction Selective serotonin reuptake inhibitors (SSRIs) and, to a lesser extent, serotonin‐
norepinephrine reuptake inhibitors (SNRIs) are the cornerstone of pharmacotherapy for …

The use of SSRIs for the treatment of depression and anxiety in young people is increasing.
However, the effects of SSRIs in adolescence, a time when there are substantial changes in …

Public Health England exists to protect and improve the nation's health and wellbeing, and
reduce health inequalities. We do this through world-leading science, research, knowledge …

Psychedelic therapy is perhaps the most exciting new development in psychiatry. Not only
does it offer a radical new approach to treatment where mainstream approaches have …

In this position statement, developed by The International College of Obsessive-Compulsive
Spectrum Disorders, a group of international experts responds to recent developments in the …